報價延遲最少15分鐘:2025/01/11 16:35 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
25.26 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.16/-1.57
|
|
企業價值
1.55B
|
| 資產負債 |
|
每股賬面淨值
15.66
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 16:35 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578. |